AACR 2024 preview – “cancer vaccines” primed to underwhelm
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
The 2024 AACR abstract title drop features several noteworthy clinical studies.
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?
Merck adds an overall survival benefit while Bristol sinks further.
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.